Decreased vasodilatory effect of Tanshinone ⅡA Sodium Sulfonate on mesenteric artery in hypertension

Eur J Pharmacol. 2019 Jul 5:854:365-371. doi: 10.1016/j.ejphar.2019.04.049. Epub 2019 May 1.

Abstract

Tanshinone ⅡA Sodium Sulfonate (DS-201), a derivative of traditional Chinese medicinal herb Danshen, has been clinically used for various cardiovascular diseases. Previous studies showed that DS-201 induced vascular relaxation partly due to the activation of the large conductance Ca2+-activated potassium (BKCa) channels. However, the efficacy of DS-201 on the resistant vessels in hypertension remains unknown. Mesentery arteries obtained from spontaneously hypertensive rats (SHR) and hypertension patients were used in this study. The endothelium-denuded mesenteric arteries were prepared to measure the artery tension and evaluate the vasodilatory effect of DS-201. The results showed that DS-201 had a vasodilatory effect on the mesenteric artery rings pre-contracted with either phenylephrine (PE) or thromboxane mimetic U46619 in a concentration-dependent manner. However, the vasodilatory effect of DS-201 significantly decreased in hypertension than in control arteries due to a decrease in protein level of BKCa β1subunit. A BKCa channel blocker IbTX (200 nM) significantly inhibited the relaxant effect of DS-201 on non-hypertensive arteries, whereas the BKCa channel specific agonist NS1619 rescued the vasodilating effects of DS-201 on hypertensive vessels. These results indicate that the vasodilating effect of DS-201 is BKCa-dependent. This study demonstrated that DS-201 alone may not be effective for treating hypertension, but it may be considered as therapy combined with BKCa-agonists or methods rescuing BKCa functions.

Keywords: A sodium sulfonate (DS-201); Hypertension; Large conductance Ca(2+)-activated potassium (BK(Ca)) channels; Mesenteric artery; Tanshinone Ⅱ; Vasodilation.

MeSH terms

  • Animals
  • Female
  • Gene Expression Regulation / drug effects
  • Humans
  • Hypertension / metabolism
  • Hypertension / physiopathology*
  • Large-Conductance Calcium-Activated Potassium Channel alpha Subunits / antagonists & inhibitors
  • Large-Conductance Calcium-Activated Potassium Channel alpha Subunits / metabolism
  • Male
  • Mesenteric Arteries / drug effects*
  • Mesenteric Arteries / physiopathology*
  • Phenanthrenes / pharmacology*
  • Rats
  • Vasoconstriction / drug effects
  • Vasodilation / drug effects*

Substances

  • KCNMA1 protein, human
  • Large-Conductance Calcium-Activated Potassium Channel alpha Subunits
  • Phenanthrenes
  • tanshinone II A sodium sulfonate